
|Videos|January 31, 2019
Lack of Durable Responses in Current Treatment of mCRC
Advertisement
Insight on the ongoing unmet needs in achieving durable responses in BRAFV600E-mutant metastatic colorectal cancer (mCRC).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5



































